Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | NR5A2 | O00482 | 2/20 | 0.74 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | FABP3 | P05413 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | PTAFR | P25105 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934318 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934690 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934304 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934555 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934547 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934652 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934630 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934616 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934533 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL29934680 | 1.00 | ALDH1A1 (0.74) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080945-A1 | LIPID NANOPARTICLES | CodeBridgeBio Inc. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2024147060-A1 | NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY | CELON PHARMA S.A. (PL) | 2024-07-11 | — | — | WO | claimed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | claimed |
| WO-2024145290-A2 | MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS | SUNVAX MRNA THERAPEUTICS (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024134512-A1 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024138013-A1 | DUAL LIPID STRUCTURES | TURN BIOTECHNOLOGIES, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024138034-A1 | IONIZABLE LIPIDS WITH DEGRADABLE HEAD | TURN BIOTECHNOLOGIES, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024134511-A2 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024123978-A1 | IONIZABLE LIPIDS WITH MALONATE TAILS | MODERNATX, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-17 | — | — | US | claimed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | claimed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | claimed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | claimed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | claimed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2016186429-A1 | COMPOSITION FOR CANCER TREATMENT COMPRISING INDOCYANINE GREEN-LIPOSOME COMPOSITE | 고려대학교산학협력단 | 2016-11-24 | — | — | WO | claimed |
| EP-2444464-A1 | Novel neutral (bio)material | Centre National de la Recherche Scientifique (CNRS) (FR) | 2012-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885NR5A2 4498/4885NR5A1 4685/4885 |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885NR5A2 4498/4885NR5A1 4685/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | ALDH1A1 4727/4885NR5A2 4085/4885NR5A1 4364/4885 |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885NR5A2 4498/4885NR5A1 4685/4885 |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | ALDH1A1 4735/4885NR5A2 3711/4885NR5A1 3516/4885 |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885NR5A2 4498/4885NR5A1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.